In vitro metabolism of a triclyclic alkaloid (M445526) in human liver microsomes and hepatocytes

Xenobiotica

Volumn 37, Issue 9, 2007, Pages 972-985

  McCormick, A D ^a   Slamon, D L ^a   Lenz, E M ^a   Phillips, P J ^a   King, C D ^a   McKillop, D ^a   Roberts, D W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Human hepatocyte metabolism; Human microsomal metabolism; Vascular targeting agent; ZD6126

Indexed keywords

ALKALOID DERIVATIVE; CARBON 14; M 445526; M 470648; M 488758; M 582198; N ACETYLCOLCHINOL PHOSPHATE; PHENOL; SULFATE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER CELL; LIVER MICROSOME; MALE; MASS SPECTROMETRY; METABOLITE; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOCHEMISTRY;

ADULT; AGED; ALKALOIDS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLCHICINE; FEMALE; HEPATOCYTES; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; TUBULIN MODULATORS;

EID: 34748824902     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701620718     Document Type: Article

References (22)

1. Blakey DC, Westwood FR, Walker M, Hughes D, Davis PD, Ashton SE, Ryan AJ. 2002. Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 8:1974-1983.
2. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. 2002. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 62:7247-7253.
3. Delproposto Z, LoRusso P, Morton P, Wheeler C, Barge A, Evelhoch J. 2002. MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature [abstract]. Proceedings of the American Society of Clinical Oncology: 21: abst 440.
4. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. 2002. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumours [abstract]. Proceedings of the American Society of Clinical Oncology 21: abst 438.
5. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. 2002. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Research 62:3711-3715.
6. Horsman MR, Murata R. 2003. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. International Journal of Radiation, Oncology, Biology, Physics 57:1047-1055.
7. Hunter AL, Klaassen CD. 1974. Biliary excretion of colchicine. Journal of Pharmacology and Experimental Therapeutics 192:605-617.
8. Judson I, Scurr M, Roberts DW, Partridge EA, D'Souza RA, Tan S. 2007. Pharmacokinetics and metabolism of ZD6126 in patients with solid tumours (In preparation).
9. McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, et al. 2004. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. British Journal of Cancer 90:705-711.
10. McKillop D, Wild MJ, Butters CJ, Simcock C. 1998. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 28:845-853.
11. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R. 2003. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research 63:1534-1537.
12. Radema SA, Beerepoot LV, Witteveen EO, Thomas T, Kempin S, Wheeler C. 2003. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumours [abstract]. Clinical Cancer Research 9(Suppl. 1): abst B34.
13. Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. 2002. Clinical evaluation of the novel vascular-targeting agent, ZD6126: Assessment of toxicity and surrogate markers of vascular damage [abstract]. Proceedings of the American Society of Clinical Oncology 21: abst 439.
14. Scurr M, Judson I, Brock C, O'Donnell A, Tan S, Partridge EA, D'Souza RA, Roberts DW. 2004. Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors [abstract]. Journal of Clinical Oncology 22(14S):3083.
15. Siemann DW, Chaplin DJ, Horsman MR. 2004. Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499.
16. Siemann DW, Rojiani AM. 2002. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation, Oncology, Biology, Physics 53:164-171.
17. Soltau J, Drevs J. 2004. ZD-6126 AstraZeneca. Idrugs 7:380-387.
18. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJJ. 1997. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochemical Pharmacology 53:111-116.
19. Thorpe PE, Chaplin DJ, Blakey DC. 2003. Meeting Report. The first international conference on vascular targeting. Cancer Research 63:1144-1147.
20. Varghese HJ, MacKenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, Chambers AF. 2004. In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 7:157-164.
21. Von Angerer E. 1999. New inhibitors of tubulin polymerisation. Expert Opinion on Therapeutic Patents 9:1069-1081.
22. Walaszek EJ, Kocsis JJ, Leroy GV, Geiling EMK. 1960. Studies on the excretion of radioactive colchicine. Archives Internationales de Pharmacodynamie et de Therapie 125:371-382.